SCHEMBL7229435

SCHEMBL7229435

Cc1cc(NS(C)(=O)=O)ccc1-c1nc(-c2ccc(F)cc2)c(-c2ccncc2)[nH]1

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX5 P09917 11/20 0.76
MAPK14 Q16539 10/20 0.59
MAPK11 Q15759 7/20 0.58
CSNK1D P48730 4/20 0.58
CSNK1E P49674 3/20 0.58
CSNK1A1 P48729 2/20 0.58
ALDH1A1 P00352 1/20 0.58
SMN1; SMN2 Q16637 1/20 0.58
CSNK1A1L Q8N752 1/20 0.58
MAPK13 O15264 6/20 0.55
GCGR P47871 6/20 0.55
MAPK12 P53778 6/20 0.55
PRKD3 O94806 1/20 0.54
MAP4K4 O95819 1/20 0.54
FRK P42685 1/20 0.54
MAPK9 P45984 1/20 0.54
GSK3B P49841 1/20 0.54
PTK6 Q13882 1/20 0.54
PRKD2 Q9BZL6 1/20 0.54
CLK4 Q9HAZ1 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4553479 0.86 ALOX5 (1.00) ALOX5MAPK14MAPK11CSNK1DCSNK1E
SCHEMBL5076146 0.85 ALOX5 (0.56) ALOX5MAPK14MAPK11CSNK1DCSNK1E
SCHEMBL5078083 0.81 ALOX5 (0.59) ALOX5MAPK14MAPK11CSNK1DCSNK1E
SCHEMBL17002223 0.77 MAPK14 (0.77) ALOX5MAPK14MAPK11CSNK1DCSNK1E
SCHEMBL16497630 0.76 ALOX5 (0.81) ALOX5MAPK14MAPK11CSNK1DCSNK1E
SCHEMBL29775509 0.76 ALOX5 (0.64) ALOX5MAPK14MAPK11CSNK1DCSNK1E
SCHEMBL3379840 0.75 TNIK (0.54) ALDH1A1CLK4
SCHEMBL6924127 0.75 ALOX5 (1.00) ALOX5MAPK14MAPK11CSNK1DCSNK1E
SCHEMBL17002186 0.74 MAPK14 (1.00) ALOX5MAPK14MAPK11CSNK1DCSNK1E
SCHEMBL9201148 0.74 MAPK14 (1.00) ALOX5MAPK14MAPK11CSNK1DCSNK1E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6288089-B1 ADMINISTERING A COMPOSITION OF PYRIDYL IMIDAZOLE COMPOUNDS TO TREAT PARKINSON'S DISEASE, HUNTINGTON'S DISEASE, ALZHEIMER'S DISEASE, AND AMYOTOPHIC LATERAL SCLEROSIS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2001-09-11 US claimed
US-5656644-A CYTOKINE SUPPRESSORS SMITHKLINE BEECHAM CORPORATION (US) 1997-08-12 US claimed
US-6645989-B2 Antiinflammatory agents SMITHKLINE BEECHAM CORPORATION 2003-11-11 US disclosed
US-20030064997-A1 Novel compounds SMITHKLINE BEECHAM CORPORATION 2003-04-03 US disclosed
US-6288089-B1 ADMINISTERING A COMPOSITION OF PYRIDYL IMIDAZOLE COMPOUNDS TO TREAT PARKINSON'S DISEASE, HUNTINGTON'S DISEASE, ALZHEIMER'S DISEASE, AND AMYOTOPHIC LATERAL SCLEROSIS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2001-09-11 US disclosed
US-6268370-B1 CYTOKINE MEDIATED DISEASES SMITHKLINE BEECHAM CORPORATION 2001-07-31 US disclosed
US-6235760-B1 CENTRAL NERVOUS SYSTEM DISORDERS; ANTIINFLAMMATORY AGENTS SMITHKLINE BEECHAM CORPORATION 2001-05-22 US disclosed
US-5656644-A CYTOKINE SUPPRESSORS SMITHKLINE BEECHAM CORPORATION (US) 1997-08-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030064997-A1 Novel compounds BRD4, BRDT, HDAC6 ALOX5 2555/4885MAPK14 3769/4885MAPK11 2198/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.